397 related articles for article (PubMed ID: 33998272)
1. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.
Ridker PM; Rane M
Circ Res; 2021 May; 128(11):1728-1746. PubMed ID: 33998272
[TBL] [Abstract][Full Text] [Related]
2. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Grebe A; Hoss F; Latz E
Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
[TBL] [Abstract][Full Text] [Related]
4. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Ridker PM; Devalaraja M; Baeres FMM; Engelmann MDM; Hovingh GK; Ivkovic M; Lo L; Kling D; Pergola P; Raj D; Libby P; Davidson M;
Lancet; 2021 May; 397(10289):2060-2069. PubMed ID: 34015342
[TBL] [Abstract][Full Text] [Related]
5. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
Ridker PM
Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
[TBL] [Abstract][Full Text] [Related]
6. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
Satish M; Agrawal DK
Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.
Westerterp M; Fotakis P; Ouimet M; Bochem AE; Zhang H; Molusky MM; Wang W; Abramowicz S; la Bastide-van Gemert S; Wang N; Welch CL; Reilly MP; Stroes ES; Moore KJ; Tall AR
Circulation; 2018 Aug; 138(9):898-912. PubMed ID: 29588315
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
9. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
Ait-Oufella H; Libby P; Tedgui A
Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
[TBL] [Abstract][Full Text] [Related]
10. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.
Rahman MM; McFadden G
J Virol; 2011 Dec; 85(23):12505-17. PubMed ID: 21957307
[TBL] [Abstract][Full Text] [Related]
11. Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives.
Melnikov I; Kozlov S; Saburova O; Avtaeva Y; Guria K; Gabbasov Z
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768404
[TBL] [Abstract][Full Text] [Related]
12. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
Ridker PM
Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102
[No Abstract] [Full Text] [Related]
13. Dopamine D1 receptor agonist A68930 attenuates acute kidney injury by inhibiting NLRP3 inflammasome activation.
Cao JY; Zhou LT; Li ZL; Yang Y; Liu BC; Liu H
J Pharmacol Sci; 2020 Jul; 143(3):226-233. PubMed ID: 32446726
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic role of innate immunity in a model of chronic NO inhibition associated with salt overload.
Zambom FFF; Oliveira KC; Foresto-Neto O; Faustino VD; Ávila VF; Albino AH; Arias SCA; Volpini RA; Malheiros DMAC; Saraiva Camara NO; Zatz R; Fujihara CK
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F1058-F1067. PubMed ID: 31411073
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial cells senescence is associated with NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation via reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP) pathway.
Yin Y; Zhou Z; Liu W; Chang Q; Sun G; Dai Y
Int J Biochem Cell Biol; 2017 Mar; 84():22-34. PubMed ID: 28064010
[TBL] [Abstract][Full Text] [Related]
17. L5-LDL from ST-elevation myocardial infarction patients induces IL-1β production via LOX-1 and NLRP3 inflammasome activation in macrophages.
Yang TC; Chang PY; Lu SC
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H265-H274. PubMed ID: 27864235
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye.
Zheng Q; Ren Y; Reinach PS; She Y; Xiao B; Hua S; Qu J; Chen W
Exp Eye Res; 2014 Aug; 125():1-8. PubMed ID: 24836981
[TBL] [Abstract][Full Text] [Related]
20. The Inhibition of NLRP3 Inflammasome and IL-6 Production by
Tomani JCD; Kagisha V; Tchinda AT; Jansen O; Ledoux A; Vanhamme L; Frederich M; Muganga R; Souopgui J
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
